Weekly Investment Analysts’ Ratings Changes for Natera (NTRA)

Several brokerages have updated their recommendations and price targets on shares of Natera (NASDAQ: NTRA) in the last few weeks:

• 7/9/2026 – Natera had its price target raised by Morgan Stanley from $250.00 to $310.00. They now have an “overweight” rating on the stock.
• 7/6/2026 – Natera had its “outperform” rating reaffirmed by Evercore Inc. They now have a $300.00 price target on the stock.
• 6/29/2026 – Natera had its price target raised by Guggenheim from $270.00 to $290.00. They now have a “buy” rating on the stock.
• 6/26/2026 – Natera is now covered by Sanford C. Bernstein. They set an “outperform” rating and a $310.00 price target on the stock.
• 6/25/2026 – Natera was upgraded by Sanford C. Bernstein to “strong-buy”.
• 6/24/2026 – Natera was given a new $275.00 price target by BTIG Research. They now have a “buy” rating on the stock.
• 6/24/2026 – Natera was given a new $260.00 price target by UBS Group AG.
• 6/24/2026 – Natera had its price target lowered by Barclays PLC from $280.00 to $260.00. They now have an “overweight” rating on the stock.
• 6/23/2026 – Natera had its price target raised by BTIG Research from $250.00 to $270.00. They now have a “buy” rating on the stock.
• 6/11/2026 – Natera is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $275.00 price target on the stock.
• 6/5/2026 – Natera is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $245.00 price target on the stock.
• 6/5/2026 – Natera is now covered by The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $245.00 price target on the stock.
• 6/2/2026 – Natera is now covered by Wolfe Research. They set an “outperform” rating and a $260.00 price target on the stock.
• 6/1/2026 – Natera was upgraded by Wolfe Research to “strong-buy”.
• 5/12/2026 – Natera had its “overweight” rating reaffirmed by Piper Sandler. They now have a $249.00 price target on the stock.
• 5/11/2026 – Natera had its price target lowered by BTIG Research from $260.00 to $250.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other news, Director Gail Boxer Marcus sold 11,000 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $217.21, for a total value of $2,389,310.00. Following the completion of the transaction, the director owned 6,183 shares of the company’s stock, valued at $1,343,009.43. This represents a 64.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $272.90, for a total value of $818,700.00. Following the sale, the insider owned 134,643 shares of the company’s stock, valued at $36,744,074.70. This represents a 2.18% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 178,872 shares of company stock worth $39,627,696 in the last three months. 5.05% of the stock is owned by company insiders.

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.